Evidence map›Paper›PMID 30694692›Full record

ArticleAmerican journal of respiratory and critical care medicine2019

Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing.

Keertan Dheda, Laura Lenders, Shashikant Srivastava, Gesham Magombedze, Helen Wainwright, Prithvi Raj, Stephen J Bush, Gabriele Pollara, Rachelle Steyn, Malika Davids and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of respiratory and critical care medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Observational
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Keertan Dheda1Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute and South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.
Laura Lenders1Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute and South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.
Shashikant Srivastava3Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas.
Gesham Magombedze3Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas.
Helen Wainwright5Department of Pathology.
Prithvi Raj4Department of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas.
Stephen J Bush3Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas.
Gabriele Pollara6Division of Infection and Immunity, University College London, London, United Kingdom; and.ORCID 0000-0001-5772-0322
Rachelle Steyn7Department of Nuclear Medicine, and.
Malika Davids1Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute and South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.
Anil Pooran1Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute and South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.
Timothy Pennel8Chris Barnard Division of Cardiothoracic Surgery, Department of Surgery, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
Anthony Linegar8Chris Barnard Division of Cardiothoracic Surgery, Department of Surgery, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
Ruth McNerney1Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute and South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.
Loven Moodley8Chris Barnard Division of Cardiothoracic Surgery, Department of Surgery, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
Jotam G Pasipanodya3Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas.
Carolin T Turner6Division of Infection and Immunity, University College London, London, United Kingdom; and.
Mahdad Noursadeghi6Division of Infection and Immunity, University College London, London, United Kingdom; and.ORCID 0000-0002-4774-0853
Robin M Warren9South African Medical Research Council Centre for Tuberculosis Research/Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Stellenbosch University, Cape Town, South Africa.
Edward Wakeland4Department of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas.
Tawanda Gumbo1Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute and South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.ORCID 0000-0001-7592-8012

Funding

Efflux pump inhibitors to reduce duration of antituberculosis therapyDP2OD001886 · OD · UT SOUTHWESTERN MEDICAL CENTER · PI GUMBO, TAWANDA · 2007 to 2007
$2.4M
PK-PD of combination antituberculosis therapy for suppression of drug-resistanceR01AI079497 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GUMBO, TAWANDA · 2008 to 2011
$2.3M
Short course therapy for MDR-TB based on PK/PD answers for biological variabilityR56AI111985 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GUMBO, TAWANDA · 2014 to 2014
$900k
Medical Research Council MR/M003833/1NIAID NIH HHS R01 AI079497NIAID NIH HHS R56 AI111985NIH HHS DP2 OD001886Wellcome TrustWellcome Trust 207511/Z/17/ZWellcome Trust WT101766/Z/13/Z
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Sequence Analysis, RNAAdolescentAdultAgedCase-Control StudiesFemaleHumansMaleMiddle AgedMycobacterium tuberculosisRNA, ViralTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryYoung AdultRNA, Viralanalysispulmonary tuberculosisTB cavitationtranscriptomics

Identifiers

PMID30694692
PMCPMC6680310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.